A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving Deep Subcutaneous Administrations of Somatuline (lanreotide) Autogel to treat the Symptoms of Functioning Midgut NeuroEndocrine Tumours (NET)

Trial Profile

A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving Deep Subcutaneous Administrations of Somatuline (lanreotide) Autogel to treat the Symptoms of Functioning Midgut NeuroEndocrine Tumours (NET)

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Pharmacodynamics
  • Acronyms CALM-NET
  • Sponsors Ipsen Limited
  • Most Recent Events

    • 29 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 07 Apr 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.
    • 07 Apr 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top